Neurological
Refine Search
Pharmaceutical
A special initiative of the Hospital for Special Surgery (HSS), designed to provide practical measures for combating the ongoing opioid epidemic in the USA, has reported a number of successes. 11 July 2019
Pharmaceutical
Leading dementia figures from universities, pharmaceutical companies and charities have identified six gaps in dementia research that present new opportunities to speed up the search for the first life-changing treatment for the condition. 11 July 2019
Pharmaceutical
UK-headquartered consumer products giant Reckitt Benckiser today announced it has reached agreements with the US Department of Justice (DoJ) and the Federal Trade Commission to resolve the long-running investigation into the sales and marketing of Suboxone (buprenorphine and naloxone) Film by its former prescription pharmaceuticals business Indivior, a business that was wholly demerged in 2014. 11 July 2019
Pharmaceutical
A new therapy for Parkinson’s disease (PD), opicapone, will be reviewed by the US Food and Drug Administration for possible marketing approval. 11 July 2019
Pharmaceutical
Family-owned Italian drugmaker Zambon and Canada’s Valeo Pharma today announced the launch of Onstryv (safinamide) for the treatment of Parkinson's disease in Canada, where it was granted marketing approval in January this year. 11 July 2019
Pharmaceutical
A new exploratory research facility, led by Japanese drugmaker Eisai, has begun full-scale research activities in Massachusetts, USA. 10 July 2019
Biotechnology
East Coast, USA-based biotech Skyhawk Therapeutics has announced the expansion of an existing collaboration with Biogen, and a new research deal with New Jersey’s Merck & Co. 8 July 2019
Pharmaceutical
Deal-making news last week featured Boehringer Ingelheim’s collaboration with Yuhan Corp on a potential treatment for non-alcoholic steatohepatitis (NASH). Additionally, the USA’s OncoSec Medical inked a CAR-T cell therapies deal with the Dana Farber Cancer Institute to target solid tumors. Japan’s Sumitomo Dainippon was forced to give up on its anti-cancer candidate napabucasin, following a DSMB recommendation finding futility. There was good news for Zogenix as the US Food and Drug Administration agreed to the company’s resubmission for Dravet syndrome drug Fintepla. 7 July 2019
Biotechnology
Israel’s leading drugmaker Teva Pharmaceutical has presented data from exploratory endpoints from the Phase IIIb FOCUS trial of Ajovy (fremanezumab), at the annual congress of the European Academy of Neurology (EAN). 2 July 2019
Biotechnology
Novartis has grabbed many of the recent headlines in the field of spinal muscular atrophy (SMA), a leading genetic cause of infant mortality. 1 July 2019
Biotechnology
Despite competition in the anti-CGRP migraine therapy space, Swiss pharma giant Novartis’ Aimovig (erenumab) has become the most-prescribed in the since its launch last year. 1 July 2019
Biotechnology
There was good news for Zogenix after a meeting with the US Food and Drug Administration (FDA). 28 June 2019
Biotechnology
In a historic decision, the US Food and Drug Administration approved Soliris (eculizumab) for a rare neurological disorder. 28 June 2019
Biotechnology
French CNS specialist Theranexus, which is developing drugs modulating the interaction between neurons and glial cells, has announced an agreement in principle with Beyond Batten Disease Foundation (BBDF). 28 June 2019
Biotechnology
The precision gene therapy company Encoded Therapeutics has announced a $104 million Series C financing. 27 June 2019
Pharmaceutical
US biopharma Titan Pharmaceuticals has clocked up a third major market approval for an opioid dependence substitutional treatment that it developed. 27 June 2019
Pharmaceutical
Of all the talk about the pros and cons of AbbVie’s $63 billion takeover of Allergan – which was announced on Tuesday – perhaps the most compelling came from Stat News. 26 June 2019
Pharmaceutical
Expectations that AbbVie would soon spend its significant cash pile have been answered by the US pharma company in a big way, with the announcement that it is to acquire Ireland-incorporated drugmaker Allergan for $63 million. 25 June 2019
Biotechnology
UK-based C4X Discovery Holdings saw its shares climb 4.55% to 52.80 pence, after announcing a collaboration with PhoreMost, a UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets. 25 June 2019
Pharmaceutical
Japanese drugmaker Shionogi has out-licensed Chinese rights for a couple of its promising assets. 24 June 2019
Pharmaceutical
Jazz Pharmaceuticals has reported third-quarter revenue of $1 billion, a 9% increase over the prior year, fueled by strong performance in its key sleep and epilepsy portfolios. 7 November 2024
Biotechnology
US clinical-stage drug developer Acumen Pharmaceuticals has appointed Amy Schacterle as chief regulatory officer and head of quality, reporting to Jim Doherty, president and chief development officer at Acumen. 7 November 2024
Pharmaceutical
Intra-Cellular Therapies has announced positive results from Study 304 evaluating the efficacy and safety of Caplyta (lumateperone) 42mg for the prevention of relapse in adult patients with schizophrenia. 6 November 2024
Pharmaceutical
US neuroscience-focused biopharma Neurocrine Biosciences presented new data from more than 300 patients diagnosed with tardive dyskinesia and treated with Ingrezza (valbenazine) capsules at the 2024 Psych Congress in Boston. 5 November 2024
Pharmaceutical
Privately-held German drugmaker Boehringer Ingelheim and researchers from the Stanley Center for Psychiatric Research at the Broad Institute of MIT and Harvard, are collaborating on a project to tackle the urgent and unmet needs of people living with mental health conditions. 4 November 2024
Pharmaceutical
US pharma major AbbVie last week proposed $1.4 billion acquisition of US CNS drug developer Aliada Therapeutics. Last week saw a bunch of third quarter 2024 financials results, among which were Elil Lilly, AbbVie and Merck & Co. Also of note, Lexicon’s type I diabetes drug Zynquista faced a Food and Drug Administration (FDA) advisory committee review that resulted in largely negative vote against recommendation. 3 November 2024
Pharmaceutical
The US subsidiary of Israel’s Teva Pharmaceutical Industries has announced new, positive data on social functioning and quality of life from the Phase III subcutaneous olanzapine extended-release injection study (SOLARIS) trial evaluating TEV-'749 in adult patients diagnosed with schizophrenia. 2 November 2024
Pharmaceutical
US pharma major AbbVie and Hungary’s Gedeon Richter have announced a new discovery, co-development and license agreement to advance novel targets for the potential treatment of neuropsychiatric conditions. 1 November 2024
Biotechnology
Dyno Therapeutics has recently announced the formation of a new strategic partnership with Swiss pharma giant Roche to develop adeno-associated virus (AAV) gene therapy vectors to target neurological diseases. 1 November 2024
Biotechnology
UCB has reported Phase IIa data from the TOGETHER (AH0003) study, investigating the safety, efficacy, and tolerability of bepranemab - an investigational anti-tau antibody targeting the mid-region of the tau protein - in people living with prodromal to mild Alzheimer’s disease. 1 November 2024
Biotechnology
Boston, USA-based biotech Axonis Therapeutics, which is focused on the development of novel neuromedicines, has announced the successful completion of an oversubscribed $115 million Series A financing. 31 October 2024
Biotechnology
US biotech companies Biogen and Neomorph have announced a research collaboration to discover and develop molecular glue degraders for priority targets in Alzheimer’s, rare neurological, and immunological diseases. 30 October 2024
Pharmaceutical
Swiss pharma giant Novartis revealed rising sales and earnings in its third-quarter financial results on Tuesday. 29 October 2024
Biotechnology
South Korea’s GemVax & KAEL has reported positive top-line results from a Phase IIa trial of GV1001, for progressive supranuclear palsy (PSP). 29 October 2024
Biotechnology
US Pharma major AbbVie has reached a definitive agreement to acquire Aliada Therapeutics, a biotech advancing therapies using a novel blood-brain barrier (BBB)-crossing technology to address challenging central nervous system (CNS) diseases. 29 October 2024
Biotechnology
Last week Vertex Pharmaceuticals released positive Phase III results for its suzetrigine for moderate-to-severed pain. Belgium’s UCB revealed that Swiss pharma giant Roche was terminating its collaboration on the Alzheimer’s candidate bepranemab. The UK’s health technology assessor the Institute for Health and Clinical Excellence (NICE) declined to recommend a second Alzheimer’s treatment, this time Eli Lilly’s Kisunla. Also of note, Lyell Immunopharma announced its planned acquisition of ImmPACT Bio and reprioritization of its own clinical pipeline. 27 October 2024
Pharmaceutical
Finnish pharma group Orion has announced it is discontinuing development of ODM-111, a pain management drug candidate, following a toxicology study suggesting it may not be suitable for long-term use. 25 October 2024
Biotechnology
US artificial intelligence (AI) to gene therapy focussed biotech Dyno Therapeutics today announced its second research collaboration with Roche to develop next-generation adeno-associated virus (AAV) vectors for gene therapies targeting neurological diseases. 24 October 2024
Biotechnology
Shares of Californian clinical-stage biotech Alto Neuroscience plummeted 70% to $4.36 yesterday, as is announced disappointing trial results for depression candidate. 24 October 2024
Pharmaceutical
Life science investors can be divided into two groups: those who bought Novo Nordisk stock before GLP-1s hit the big time, and those who wish they had. 23 October 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze